Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy.

Area of Science:

• Epigenetics and Molecular Oncology
• Drug Discovery and Medicinal Chemistry

Background:

• Histone deacetylases (HDACs) are key epigenetic regulators implicated in cancer development.
• Current FDA-approved HDAC inhibitors, while effective, possess limitations like metabolic instability and genotoxicity due to conventional zinc-binding groups (ZBGs).
• There is a critical need for novel HDAC inhibitors with improved safety and pharmacokinetic profiles.

Purpose of the Study:

• To provide a comprehensive review of recently developed HDAC inhibitors.
• To analyze structure-activity relationships (SARs), chemical scaffolds, and binding features of novel HDAC inhibitors.
• To evaluate the potency and selectivity of these inhibitors against various cancer types and HDAC isoforms.

Main Methods:

• Literature review of HDAC inhibitors reported in recent years.
• Analysis of chemical structures, including cap, linker, and ZBG motifs.
• Evaluation of SARs, potency, selectivity, and pharmacokinetic properties of hydroxamate-based and non-hydroxamate inhibitors.
• Discussion of emerging dual-target HDAC inhibitors.

Main Results:

• Numerous novel HDAC inhibitors with diverse chemical scaffolds and alternative ZBGs have been developed.
• Non-hydroxamate inhibitors (e.g., benzamides, hydrazides, thiols) show promise for improved safety and pharmacokinetics.
• Emerging dual-target inhibitors (e.g., HDAC-tubulin, HDAC-PI3K, HDAC-CDK) demonstrate synergistic anticancer activity.

Conclusions:

• Novel HDAC inhibitors, particularly those with non-hydroxamate ZBGs, offer potential for safer and more effective cancer therapies.
• Understanding SARs and binding features is crucial for designing potent and selective HDAC inhibitors.
• Dual-targeting strategies represent a promising avenue for overcoming drug resistance and enhancing therapeutic outcomes in oncology.